melanoma,Gene,Uniprot,Protein,Overexpression,Affinity 000,Type 000,SMILES 000,ID 000,Affinity 001,Type 001,SMILES 001,ID 001,Affinity 002,Type 002,SMILES 002,ID 002
melanoma,NTRK3,Q16288,NT-3 growth factor receptor (EC 2.7.10.1) (GP145-TrkC) (Trk-C) (Neurotrophic tyrosine kinase receptor type 3) (TrkC tyrosine kinase),62.68,0.503,IC50,COc1ccc(COc2ccc(Cn3c(N)nc4cc(cnc34)-c3cnn(C)c3)cc2OC)cc1,164901,0.525,IC50,CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,130909,1.0,IC50,Fc1cccc(c1)[C@H]1CCCN1c1ccc2ncc(-c3ccccn3)n2n1,50092079
melanoma,MMP14,P50281,Matrix metalloproteinase-14 (MMP-14) (EC 3.4.24.80) (MMP-X1) (Membrane-type matrix metalloproteinase 1) (MT-MMP 1) (MTMMP1) (Membrane-type-1 matrix metalloproteinase) (MT1-MMP) (MT1MMP),19.84,0.2,IC50,Nc1nc2c(nccc2[nH]1)-c1cc(Br)c(Br)[nH]1,50215926,0.3,IC50,CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1,50082556,0.32,IC50,CC(C)[C@@H](N(CC(=O)NCCc1ccc(cc1)S(N)(=O)=O)S(=O)(=O)c1ccc(Oc2ccccc2)cc1)C(=O)NO,50246599
melanoma,CTSB,P07858,Cathepsin B (EC 3.4.22.1) (APP secretase) (APPS) (Cathepsin B1) [Cleaved into: Cathepsin B light chain; Cathepsin B heavy chain],18.54,0.077,Ki,C[C@@H](CC1CCCCC1)OC(=O)NN(C)C#N,50167289,0.2,Ki,CCC(NC(=O)C(CC(C)C)NC(=O)OCc1ccccc1)C(=O)C(=O)NCCCc1ccccc1,50042414,0.2,Ki,CCC(NC(=O)C(CC(C)C)NC(=O)OCc1ccccc1)C(=O)C(=O)NCCc1ccccn1,50053797
melanoma,QPCT,Q16769,Glutaminyl-peptide cyclotransferase (EC 2.3.2.5) (Glutaminyl cyclase) (QC) (sQC) (Glutaminyl-tRNA cyclotransferase) (Glutamyl cyclase) (EC),17.41,2.4869,Ki,Fc1c(F)c(ccc1[C@H]1COC(=O)N1c1ccc2[nH]cnc2c1)N1CCC(F)(F)C1,259915,2.5297,Ki,Fc1c(F)c(ccc1[C@H]1COC(=O)N1c1ccc2[nH]cnc2c1)N1CCC(F)(F)C1,259915,2.6,Ki,COc1ccc(cc1OC)C1(CC1)C(=S)NCCCn1cncc1C,50299858
melanoma,HSPCB,P08238,Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84),15.77,0.064,Ki,CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O,20926,0.069,Ki,CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O,20926,0.35,Kd,O=C(N[C@@H]1c2ccccc2-c2c1cccc2-c1nc2ccncc2[nH]1)c1ccnc2[nH]ccc12,50357454
melanoma,EDNRB,P24530,Endothelin receptor type B (ET-B) (ET-BR) (Endothelin receptor non-selective type),12.44,0.1,Ki,CCCCc1ccc2[C@@H]([C@H]([C@@H](c2n1)c1ccc(OC)cc1C[C@H](C)C(O)=O)C(O)=O)c1ccc2OCOc2c1,50143784,0.14,IC50,CCCN(CCN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)c(F)c1)C(O)=O)c1ccc2OCOc2c1)S(=O)(=O)CCCCl,50061086,0.14,Ki,CN([C@H](Cc1ccc(cc1)-c1ccno1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NS(=O)(=O)C=C)C(=O)c1cc(C)cc(C)c1,50071445
melanoma,CDK5,Q00535,Cyclin-dependent-like kinase 5 (EC 2.7.11.1) (Cell division protein kinase 5) (Serine/threonine-protein kinase PSSALRE) (Tau protein kinase II catalytic subunit) (TPKII catalytic subunit),12.06,1.0,IC50,CC(C)c1n[nH]c2c(NCc3ccc(cc3)-c3ccccn3)nc(NCC(C)(C)O)nc12,50154931,3.8,IC50,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579,4.0,IC50,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579
melanoma,SRC,P12931,Proto-oncogene tyrosine-protein kinase Src (EC 2.7.10.2) (Proto-oncogene c-Src) (pp60c-src) (p60-Src),11.47,0.15,IC50,COc1cc(Nc2c(cnc3cc4cc(OCCN5CCOCC5)c(OC)cc4cc23)C#N)c(C)cc1Cl,6469,0.2,IC50,CCN(CC)CC=Cc1[nH]c(=O)c2c3n(C)c(Nc4c(Cl)cccc4Cl)nc3ccc2c1C,50126732,0.21,Kd,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1,13216
melanoma,CDK2,P24941,Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase),10.92,0.11,Ki,COCCNS(=O)(=O)c1ccc(Nc2nccc(n2)-c2sc(=O)n(C)c2C)cc1,81438,0.3,IC50,[O-][N+](=O)c1cccc(Nc2nccc(n2)-c2cnn3ncccc23)c1,50293153,0.36,IC50,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579
melanoma,CDC2L6,Q9BWU1,Cyclin-dependent kinase 19 (EC 2.7.11.22) (CDC2-related protein kinase 6) (Cell division cycle 2-like protein kinase 6) (Cell division protein kinase 19) (Cyclin-dependent kinase 11) (Death-preventing kinase),10.89,1.5,Kd,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,31085,1.5,Kd,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,31085,,,,
melanoma,AKT1,P31749,RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (Proto-oncogene c-Akt) (RAC-PK-alpha),9.76,0.04,Ki,NCC(Cc1ccccc1)NC(=O)c1cc(Br)c(s1)-c1ccnc2[nH]ccc12,50278693,0.05,Ki,NC[C@H](Cc1ccccc1C(F)(F)F)NC(=O)c1cc(Br)c(s1)-c1ccnc2[nH]ccc12,50278098,0.06,Ki,NC[C@H](Cc1ccc(F)cc1)NC(=O)c1cc(Br)c(s1)-c1ccnc2[nH]ccc12,50278837
melanoma,JUN,P05412,Transcription factor AP-1 (Activator protein 1) (AP1) (Proto-oncogene c-Jun) (V-jun avian sarcoma virus 17 oncogene homolog) (p39),9.69,3.0,IC50,COc1ccc2nc(nc(NN3C(=O)C=C(C)C3=O)c2c1)-c1cccs1,50135483,8.0,IC50,COc1cccc2nc(nc(NN3C(=O)C=C(C)C3=O)c12)-c1cccs1,50135482,,,,
melanoma,CSNK1G2,P78368,Casein kinase I isoform gamma-2 (CKI-gamma 2) (EC 2.7.11.1),9.14,3.0,IC50,COc1cnc(COc2ccc(F)cc2C)cc1-c1cc2c(CCNC2=O)[nH]1,50400754,3.0,IC50,COc1cnc(COc2ccc(F)cc2F)cc1-c1cc2c(CCNC2=O)[nH]1,50400756,4.0,IC50,COc1cnc(COc2cc(F)c(F)cc2C)cc1-c1cc2c(CCNC2=O)[nH]1,50400753
melanoma,MC1R,Q01726,Melanocyte-stimulating hormone receptor (MSH-R) (Melanocortin receptor 1) (MC1-R),8.79,0.0,EC50,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2C[C@@H](CN2C(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)N=C(N)N)C(N)=O,50268799,0.0,EC50,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2C[C@@H](CN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)N=C(N)N)C(N)=O,50268793,0.002,EC50,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CCC(=O)NCC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O)C(=O)N[C@@H](Cc1cccc2ccccc12)C(N)=O,250661
melanoma,SERPINE1,P05121,Plasminogen activator inhibitor 1 (PAI) (PAI-1) (Endothelial plasminogen activator inhibitor) (Serpin E1),8.6,3.1,Kd,Oc1cc(cc(O)c1O)C(=O)OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(O)c2)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@H]1OC(=O)c1cc(O)c(O)c(O)c1,92485,3.1,Kd,Oc1cc(cc(O)c1O)C(=O)OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(O)c2)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@H]1OC(=O)c1cc(O)c(O)c(O)c1,92485,5.3,Kd,Oc1cc(cc(O)c1O)C(=O)OCC(COC(=O)c1cc(O)c(O)c(O)c1)OC(=O)c1cc(O)c(O)c(O)c1,92486
melanoma,BMP1,P13497,Bone morphogenetic protein 1 (BMP-1) (EC 3.4.24.19) (Mammalian tolloid protein) (mTld) (Procollagen C-proteinase) (PCP),8.58,0.024,IC50,COc1ccc(cc1)S(=O)(=O)N(Cc1ccc2OCOc2c1)[C@@H](C(=O)NO)C(=O)C(N)CNC(=O)OCC1c2ccccc2-c2ccccc12,50111856,0.2,IC50,COc1ccc(cc1)S(=O)(=O)N(Cc1ccc2OCOc2c1)[C@H](Cc1cccs1)C(=O)NO,50111848,0.2,IC50,COc1ccc(cc1)S(=O)(=O)N(Cc1ccc2OCOc2c1)[C@H](Cc1cccs1)C(=O)NO,50111848
melanoma,SCARB1,Q8WTV0,"Scavenger receptor class B member 1 (SRB1) (CD36 and LIMPII analogous 1) (CLA-1) (CD36 antigen-like 1) (Collagen type I receptor, thrombospondin receptor-like 1) (SR-BI) (CD antigen CD36)",8.48,1.5,IC50,Cc1noc(n1)-c1ccc2n(CCCSc3cc(F)cc(F)c3)c3CCCCc3c2c1,50397852,1.5,IC50,CCc1cc(CC)nc(OCCCn2c3CCCC(=O)c3c3cc(ccc23)-c2nc(C)no2)n1,50397855,1.5,IC50,Cc1noc(n1)-c1ccc2n(CC(F)COc3cc(F)cc(F)c3)c3CCCCc3c2c1,50397857
melanoma,UGCG,Q16739,Ceramide glucosyltransferase (EC 2.4.1.80) (GLCT-1) (Glucosylceramide synthase) (GCS) (UDP-glucose ceramide glucosyltransferase) (UDP-glucose:N-acylsphingosine D-glucosyltransferase),8.31,0.3,IC50,CN1CCN(CC1)C(=O)[C@@H](COCc1ccc2OCCOc2c1)NC(=O)c1cccnc1Oc1ccc(cc1Cl)C(F)(F)F,50356075,1.0,IC50,CN1CCN(CC1)C(=O)[C@@H](COCc1ccc2OCCOc2c1)NC(=O)c1cccnc1Oc1ccc(cc1Cl)C(F)(F)F,50356075,1.0,IC50,CN1CCN(CC1)C(=O)[C@@H](COCc1ccccc1)NC(=O)c1cccnc1Oc1ccc(cc1Cl)C(F)(F)F,50356076
melanoma,BRD2,P25440,Bromodomain-containing protein 2 (O27.1.1) (Really interesting new gene 3 protein),8.11,3.2,IC50,C[C@H]1C[C@@H](Nc2ccc(Cl)cc2)c2cc(ccc2N1C(C)=O)-c1ccc(cc1)C(O)=O,50028142,5.4,Ki,Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1,50092312,6.2,Kd,Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1,50365262
melanoma,MAP2K2,P36507,Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2),8.07,3.9,Kd,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,50308060,3.9,Kd,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,50308060,9.9,Kd,COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl,4552
melanoma,PDE6D,O43924,"Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta (GMP-PDE delta) (Protein p17)",8.02,0.077,Kd,O=C(OC[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1)C1CCN(CC1)c1nc2ccccc2n1Cc1ccccc1,50019866,1.1,Kd,C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1,50019865,6.0,Kd,Cc1nc2ccccc2n1CCOC(=O)C1CCN(CC1)c1nc2ccccc2n1Cc1ccccc1,50019850
melanoma,BACE2,Q9Y5Z0,Beta-secretase 2 (EC 3.4.23.45) (Aspartic-like protease 56 kDa) (Aspartyl protease 1) (ASP1) (Asp 1) (Beta-site amyloid precursor protein cleaving enzyme 2) (Beta-site APP cleaving enzyme 2) (Down region aspartic protease) (DRAP) (Memapsin-1) (Membrane-associated aspartic protease 1) (Theta-secretase),7.54,0.0014,Ki,CCCC(O)C(NCC(O)C(Cc1ccccc1)NC(=O)c1cc(C)cc(c1)C(=O)N(C)C(C)c1ccccc1)C(=O)NCC(C)C,172740,0.02,Ki,CCCC(O)C(NCC(O)C(Cc1ccccc1)NC(=O)c1cccc(c1)C(=O)N(C)C(C)c1ccccc1)C(=O)NCC(C)C,172750,0.22,Ki,CN1C(=N)N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(Cl)cn2)ccc1F,143218
melanoma,HSPCA,P07900,Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Lipopolysaccharide-associated protein 2) (LAP-2) (LPS-associated protein 2) (Renal carcinoma antigen NY-REN-38),7.38,0.04,IC50,CCOC(=O)NCc1ccc(cc1)-n1c(n[nH]c1=S)-c1cc(C(C)C)c(O)cc1O,81917,0.043,Kd,CN(C)c1ccc(Oc2cc(O)cc(O)c2-c2cc(on2)C(=O)NC2CCN(CC2)C2CCC3(CC2)OCCO3)cc1,152279,0.057,Kd,CN(C)c1ccc(Oc2cc(O)cc(O)c2-c2cc(no2)C(=O)NC2CCN(CC2)C2CCC3(CC2)OCCO3)cc1,50442757
melanoma,STK10,O94804,Serine/threonine-protein kinase 10 (EC 2.7.11.1) (Lymphocyte-oriented kinase),7.0,0.03,Kd,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579,0.037,Kd,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579,0.037000000000000005,Kd,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579
melanoma,PRKCD,Q05655,Protein kinase C delta type (EC 2.7.11.13) (Tyrosine-protein kinase PRKCD) (EC 2.7.10.2) (nPKC-delta) [Cleaved into: Protein kinase C delta type regulatory subunit; Protein kinase C delta type catalytic subunit (Sphingosine-dependent protein kinase-1) (SDK1)],6.98,0.1,IC50,CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3c(C)cccc23)c2ccccc2n1,50393214,0.14,Ki,CCCC(=O)O[C@@]12C(C3CC(=O)C[C@@]4(O)C(C=C(C)C4=O)[C@]3(O)[C@@H](C)[C@H]1OC(=O)c1ccccc1NC)C2(C)C,92596,0.177,Kd,CCCC(=O)O[C@@H]1[C@H](C)[C@@]2(O)C3C=C(C)C(=O)[C@@]3(O)CC(=O)CC2C2C(C)(C)[C@@]12OC(=O)CCC,92594
melanoma,TKT,P29401,Transketolase (TK) (EC 2.2.1.1),6.83,3.0,Kd,CC(=O)Nc1ncc(Cc2csc(CCO)c2C)c(N)n1,50373882,4.7,EC50,CC(=O)OCCc1sc[n+](Cc2ccc(C)nc2N)c1C,50373745,7.0,Kd,Cc1c(CCO)sc[n+]1Cc1ccc(N)nc1,50373735
melanoma,FOLR1,P15328,"Folate receptor alpha (FR-alpha) (Adult folate-binding protein) (FBP) (Folate receptor 1) (Folate receptor, adult) (KB cells FBP) (Ovarian tumor-associated antigen MOv18)",6.78,0.0005,Kd,Nc1nc2NCC(CCc3ccc(s3)C(=O)N[C@H](CCC(O)=O)C(O)=O)Sc2c(=O)[nH]1,50059333,0.002,Kd,Nc1nc2NCC(CCc3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)Sc2c(=O)[nH]1,50059339,0.0032,Kd,Nc1nc2NCC(CCc3ccc(s3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)Sc2c(=O)[nH]1,50059335
melanoma,P2RX7,Q99572,P2X purinoceptor 7 (P2X7) (ATP receptor) (P2Z receptor) (Purinergic receptor),6.67,0.01,IC50,C[C@H](CN)n1ccc2c(NC(=O)Cc3ccc(c(F)c3)C(F)(F)F)c(C)ccc2c1=O,50426571,0.0501,IC50,CC(C)C(CO)n1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2c1=O,50414304,0.0794,IC50,CC(C(N)=O)n1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)c(Cl)ccc2c1=O,50414307
melanoma,MAP3K12,Q12852,Mitogen-activated protein kinase kinase kinase 12 (EC 2.7.11.25) (Dual leucine zipper bearing kinase) (DLK) (Leucine-zipper protein kinase) (ZPK) (MAPK-upstream kinase) (MUK) (Mixed lineage kinase),6.5,0.2,Ki,N#Cc1ccnc(Nc2cc(cc(OC3CCC3)n2)C2CCN(CC2)C2COC2)c1,50059194,0.7,Ki,FC1(F)CCN(C1)c1cc(cc(Nc2cc(ccn2)C#N)n1)C1CN(C1)C1COC1,50059191,0.9,Ki,FC1(F)CCN(C1)c1cc(cc(Nc2cc(ccn2)C#N)n1)C1CCOCC1,50059201
melanoma,FYN,P06241,Tyrosine-protein kinase Fyn (EC 2.7.10.2) (Proto-oncogene Syn) (Proto-oncogene c-Fyn) (Src-like kinase) (SLK) (p59-Fyn),6.48,0.4,Kd,Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(c2)C(N)=O)n1,26145,0.5,IC50,CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12,50142887,0.79,Kd,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1,13216
melanoma,GART,P22102,Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase (EC 6.3.4.13) (Glycinamide ribonucleotide synthetase) (GARS) (Phosphoribosylglycinamide synthetase); Phosphoribosylformylglycinamidine cyclo-ligase (EC 6.3.3.1) (AIR synthase) (AIRS) (Phosphoribosyl-aminoimidazole synthetase); Phosphoribosylglycinamide formyltransferase (EC 2.1.2.2) (5'-phosphoribosylglycinamide transformylase) (GAR transformylase) (GART)],6.44,5e-05,IC50,Nc1nc2NCC(CCCc3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)Nc2c(=O)[nH]1,50016658,0.00055,IC50,CC(CC1=Nc2c(NC1)nc(N)[nH]c2=O)Cc1ccc(cc1)C(=O)NC(CCC(O)=O)C(O)=O,50016662,0.001,IC50,Nc1nc2NC[C@H](CCNc3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)Nc2c(=O)[nH]1,50016660
melanoma,ITPR3,Q14573,"Inositol 1,4,5-trisphosphate receptor type 3 (IP3 receptor isoform 3) (IP3R 3) (InsP3R3) (Type 3 inositol 1,4,5-trisphosphate receptor) (Type 3 InsP3 receptor)",6.43,1.17,Kd,CN(C)c1ccc(cc1)[C+](c1ccc(cc1)N(C)C)c1ccc(cc1)C(=O)NCCCOP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1O,50078572,2.9,IC50,O[C@H]1[C@@H](OP(O)(O)=O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1OP(O)(O)=O,50075651,6.1,IC50,O[C@@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O,50075647
melanoma,HSPA8,P11142,Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) (Lipopolysaccharide-associated protein 1) (LAP-1) (LPS-associated protein 1),6.43,,,,,,,,,,,,
melanoma,IGF1R,P08069,Insulin-like growth factor 1 receptor (EC 2.7.10.1) (Insulin-like growth factor I receptor) (IGF-I receptor) (CD antigen CD221) [Cleaved into: Insulin-like growth factor 1 receptor alpha chain; Insulin-like growth factor 1 receptor beta chain],6.39,0.11,IC50,COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2C(N)=O)n1)P(C)(C)=O,50185287,0.18,IC50,COc1cc(OCCN2CCCC2)ccc1Nc1ncc2CCc3nn(C)c(c3-c2n1)-c1ccccc1Cl,122557,0.19,IC50,COc1cc(ccc1Nc1ncc2C(C)Cc3nn(C)c(c3-c2n1)-c1ccccc1Cl)N1CCN(C)CC1,122627
melanoma,PPIB,P23284,Peptidyl-prolyl cis-trans isomerase B (PPIase B) (EC 5.2.1.8) (CYP-S1) (Cyclophilin B) (Rotamase B) (S-cyclophilin) (SCYLP),6.24,1.0,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O)C(C)C,50339127,1.2,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H]([C@@H](C)CN2CCN(CCOC)CC2)N(C)C(=O)[C@@H](C)N(C)C1=O)C(C)C,50030493,2.9,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@H](SCCN(C)C)N(C)C1=O)C(C)C,50323721
melanoma,NR1H2,P55055,Oxysterols receptor LXR-beta (Liver X receptor beta) (Nuclear receptor NER) (Nuclear receptor subfamily 1 group H member 2) (Ubiquitously-expressed nuclear receptor),6.17,0.6,IC50,CS(=O)(=O)c1cc(ccc1CO)-c1ccc(CN(Cc2ccccc2)S(=O)(=O)c2ccccc2C(F)(F)F)s1,50177010,1.0,IC50,CC1(CCC[C@@]2(C)[C@H]1CCc1ccc(O)cc21)C(=O)NC(=O)[C@@]1(C)CCC[C@@]2(C)[C@H]1CCc1ccc(O)cc21,50167697,1.0,EC50,CC1(CCC[C@@]2(C)[C@H]1CCc1ccc(O)cc21)C(=O)NC(=O)[C@@]1(C)CCC[C@@]2(C)[C@H]1CCc1ccc(O)cc21,50167697
melanoma,MMP17,Q9ULZ9,Matrix metalloproteinase-17 (MMP-17) (EC 3.4.24.-) (Membrane-type matrix metalloproteinase 4) (MT-MMP 4) (MTMMP4) (Membrane-type-4 matrix metalloproteinase) (MT4-MMP) (MT4MMP),6.07,3.4,IC50,CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO,50062351,5.7,IC50,CC(C)C[C@H](CC(=O)NO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,50035507,,,,
melanoma,OPRS1,Q99720,Sigma non-opioid intracellular receptor 1 (Aging-associated gene 8 protein) (SR31747-binding protein) (SR-BP) (Sigma 1-type opioid receptor) (SIG-1R) (Sigma1-receptor) (Sigma1R) (hSigmaR1),5.82,0.01,Ki,CC(CN1C[C@H](C)O[C@H](C)C1)Cc1ccc(cc1)C(C)(C)C,50170654,0.036000000000000004,Ki,C(CCN1CCN(CC1)C1CCCCC1)CC1CCCc2ccccc12,50145021,0.04,Ki,CCCCCCCCCCCCCN1C[C@H](C)O[C@H](C)C1,50170652
melanoma,MIF,P14174,Macrophage migration inhibitory factor (MIF) (EC 5.3.2.1) (Glycosylation-inhibiting factor) (GIF) (L-dopachrome isomerase) (L-dopachrome tautomerase) (EC 5.3.3.12) (Phenylpyruvate tautomerase),5.68,7.5,IC50,Cc1ccc2n(Cc3cccc(O)c3)c(=O)oc2c1,50327348,10.0,IC50,Cc1ccc2oc(=O)n(Cc3cccc(O)c3)c2c1,50327346,,,,
melanoma,NUDT1,P36639,"7,8-dihydro-8-oxoguanine triphosphatase (EC 3.6.1.55) (2-hydroxy-dATP diphosphatase) (EC 3.6.1.56) (8-oxo-dGTPase) (Nucleoside diphosphate-linked moiety X motif 1) (Nudix motif 1)",5.68,0.2,IC50,CN(CC(C)(C)C)c1nc(N)ncc1C,50152127,0.2,IC50,Cc1cnc(N)nc1OCC(C)(C)C,50152144,0.5,IC50,CN(CC(C)(C)CO)c1nc(N)ncc1C,50152129
melanoma,PPIF,P30405,"Peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIase F) (EC 5.2.1.8) (Cyclophilin D) (CyP-D) (CypD) (Cyclophilin F) (Mitochondrial cyclophilin) (CyP-M) (Rotamase F)",5.58,0.9,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H]([C@@H](C)CN2CCN(CCOC)CC2)N(C)C(=O)[C@@H](C)N(C)C1=O)C(C)C,50030493,1.0,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O)C(C)C,50339127,3.1,Kd,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@H](SCCN(C)C)N(C)C1=O)C(C)C,50323721
melanoma,BRD9,Q9H8M2,Bromodomain-containing protein 9 (Rhabdomyosarcoma antigen MU-RMS-40.8),5.49,0.75,Kd,COc1cc(cc(OC)c1CN(C)C)-c1cn(C)c(=O)c2cnccc12,50183448,2.0,Kd,CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1,50147620,5.9,Kd,COc1cc(c(OC)cc1CN(C)C)-c1cn(C)c(=O)c2cnccc12,50183449
melanoma,CDK9,P50750,Cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (C-2K) (Cell division cycle 2-like protein kinase 4) (Cell division protein kinase 9) (Serine/threonine-protein kinase PITALRE) (Tat-associated kinase complex catalytic subunit),5.45,0.005,IC50,COc1ccc(F)cc1-c1cc(NC(=O)COc2ccc(Cl)cn2)ncn1,120943,0.015,IC50,COc1ccc(F)cc1-c1cc(NC(=O)Cc2cccnc2)ncn1,120941,0.018000000000000002,IC50,COc1ccc(F)cc1-c1cc(NC(=O)C2CCCNC2)ncn1,120934
melanoma,PSEN2,P49810,Presenilin-2 (PS-2) (EC 3.4.23.-) (AD3LP) (AD5) (E5-1) (STM-2) [Cleaved into: Presenilin-2 NTF subunit; Presenilin-2 CTF subunit],5.3,1.0,IC50,CS(=O)(=O)CC[C@@H]1OCC[C@@]2([C@H]1COc1c(F)ccc(F)c21)S(=O)(=O)c1ccc(Cl)cc1,50393452,2.0,IC50,CCS(=O)(=O)CC[C@@H]1OCC[C@@]2([C@H]1COc1c(F)ccc(F)c21)S(=O)(=O)c1ccc(Cl)cc1,50393453,3.0,IC50,CC(C)S(=O)(=O)CC[C@@H]1OCC[C@@]2([C@H]1COc1c(F)ccc(F)c21)S(=O)(=O)c1ccc(Cl)cc1,50393454
melanoma,TYMS,P04818,Thymidylate synthase (TS) (TSase) (EC 2.1.1.45),5.18,0.040999999999999995,Ki,Nc1nc2ccc(CN(CC#C)c3ccc(cc3)C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O)cc2c(=O)[nH]1,50405732,0.042,Ki,Nc1nc2ccc(CN(CC#C)c3ccc(cc3)C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O)cc2c(=O)[nH]1,50405733,0.07200000000000001,Ki,Nc1nc2ccc(CN(CC#C)c3ccc(cc3)C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)cc2c(=O)[nH]1,50405731
melanoma,ADAM10,O14672,Disintegrin and metalloproteinase domain-containing protein 10 (ADAM 10) (EC 3.4.24.81) (CDw156) (Kuzbanian protein homolog) (Mammalian disintegrin-metalloprotease) (CD antigen CD156c),5.09,6.2,IC50,Cc1ccccc1C1CCN(CC1)S(=O)(=O)CC1(CCN(CC1)C(=O)OC1CCCC1O)C(=O)NO,50229655,6.5,IC50,Cc1cc(ccc1C1CCN(CC1)S(=O)(=O)CC1(CCN(CC1)C(=O)OC[C@@H]1CCCN1)C(=O)NO)C#N,50229651,7.1,IC50,ONC(=O)C1(CS(=O)(=O)N2CCC(=CC2)c2ccccc2)CCN(CC1)C(=O)O[C@H]1CCOC1,50229639
melanoma,FKBP1A,P62942,Peptidyl-prolyl cis-trans isomerase FKBP1A (PPIase FKBP1A) (EC 5.2.1.8) (12 kDa FK506-binding protein) (12 kDa FKBP) (FKBP-12) (Calstabin-1) (FK506-binding protein 1A) (FKBP-1A) (Immunophilin FKBP12) (Rotamase),5.03,0.01,Ki,CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1,23334,0.2,Kd,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,50030448,0.2,Kd,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,50030448
melanoma,PCTK1,Q00536,Cyclin-dependent kinase 16 (EC 2.7.11.22) (Cell division protein kinase 16) (PCTAIRE-motif protein kinase 1) (Serine/threonine-protein kinase PCTAIRE-1),5.0,0.54,Kd,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,12621,1.1,Kd,Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1,24654,7.1,Kd,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,5931
melanoma,PKN1,Q16512,Serine/threonine-protein kinase N1 (EC 2.7.11.13) (Protease-activated kinase 1) (PAK-1) (Protein kinase C-like 1) (Protein kinase C-like PKN) (Protein kinase PKN-alpha) (Protein-kinase C-related kinase 1) (Serine-threonine protein kinase N),5.0,1.0,IC50,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579,1.2,IC50,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579,1.3,Kd,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579
melanoma,EIF4A1,P60842,Eukaryotic initiation factor 4A-I (eIF-4A-I) (eIF4A-I) (EC 3.6.4.13) (ATP-dependent RNA helicase eIF4A-1),4.98,0.2,EC50,COC(=O)[C@H]1[C@@H](O)[C@@]2(O)c3c(O[C@]2([C@@H]1c1ccccc1)c1ccc(OC)cc1)cc(cc3OC)C(=O)OC,50397421,0.5,IC50,CONC(=O)[C@H]1[C@@H](O)[C@@]2(O)c3c(O[C@]2([C@@H]1c1ccccc1)c1ccc(OC)cc1)cc(OC)cc3OC,50388144,0.6,EC50,COc1ccc(cc1)[C@@]12Oc3cc(Cl)cc(OC)c3[C@]1(O)[C@H](O)[C@@H]([C@H]2c1ccccc1)C(=O)N(C)C,50397420
melanoma,AHCY,P23526,Adenosylhomocysteinase (AdoHcyase) (EC 3.3.1.1) (S-adenosyl-L-homocysteine hydrolase),4.87,0.5,Ki,Nc1ncnc2n(cnc12)C(OC(=C)C=O)C=O,50240434,1.3,IC50,Nc1ncc(F)c2n(cnc12)[C@@H]1CC[C@@H](O)[C@H]1O,50018507,1.5,IC50,Nc1ncnc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O,50006222
melanoma,PLAUR,Q03405,Urokinase plasminogen activator surface receptor (U-PAR) (uPAR) (Monocyte activation antigen Mo3) (CD antigen CD87),4.77,1.0,Ki,Nc1c(cc(-c2ccccc2)n1-c1ccncc1)-c1nc2ccccc2[nH]1,50402366,1.1,Ki,Nc1c(cc(-c2ccccc2)n1-c1ccc(Br)cc1)-c1nc2ccccc2[nH]1,50402364,1.2,Ki,Nc1c(cc(-c2ccccc2)n1-c1cccc(Br)c1)-c1nc2ccccc2[nH]1,50402365
melanoma,STAT6,P42226,Signal transducer and activator of transcription 6 (IL-4 Stat),4.74,0.7,IC50,NC(=O)c1cnc(Nc2ccc(cc2)N2CCOCC2)nc1NCc1c(F)cc(F)cc1F,50243934,0.7,IC50,NC(=O)c1cnc(Nc2ccc(cc2)N2CCOCC2)nc1NCc1c(F)ccc(F)c1F,50304425,1.4,IC50,NC(=O)c1cnc(Nc2ccc(cc2)N2CCOCC2)nc1NCc1ccccc1F,50244291
melanoma,MMP11,P24347,Stromelysin-3 (SL-3) (ST3) (EC 3.4.24.-) (Matrix metalloproteinase-11) (MMP-11),4.7,0.23,Ki,COc1ccccc1SC[C@H](CP(O)(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,50265077,5.0,Ki,NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCCc1ccccc1)CP(O)(=O)C(Cc1ccccc1)NC(=O)OCc1ccccc1,50138684,5.0,Ki,NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCc1ccccc1)CP(O)(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1,50393211
melanoma,CSNK2A1,P68400,Casein kinase II subunit alpha (CK II alpha) (EC 2.7.11.1),4.64,0.00025,Kd,CN(CCN)c1ccc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)cc1NC(C)=O,50172243,0.13,IC50,Cc1nc(Nc2nc(Nc3ccc4n(C)nc(C#N)c4c3)nn3c(cnc23)[N+]#[C-])nn1C,142829,0.14,IC50,COC(=O)N[C@@H]1CCN(C[C@@H]1F)c1cc(cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c1Cl)C#N,142817
melanoma,BMPR2,Q13873,Bone morphogenetic protein receptor type-2 (BMP type-2 receptor) (BMPR-2) (EC 2.7.11.30) (Bone morphogenetic protein receptor type II) (BMP type II receptor) (BMPR-II),4.63,,,,,,,,,,,,
melanoma,DYRK1B,Q9Y463,Dual specificity tyrosine-phosphorylation-regulated kinase 1B (EC 2.7.12.1) (Minibrain-related kinase) (Mirk protein kinase),4.56,0.24,IC50,COC(=N)c1nc2ccc3ncnc(Nc4ccc(F)cc4Br)c3c2s1,50434358,0.24,IC50,COC(=N)c1nc2ccc3ncnc(Nc4ccc(Br)cc4F)c3c2s1,50434356,0.28,IC50,COC(=N)c1nc2ccc3ncnc(Nc4ccc(Cl)cc4Cl)c3c2s1,50434353
melanoma,CALM1,P0DP23,Calmodulin-1,4.42,1.0,Kd,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN)[C@@H](C)O)C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O,50045365,10.0,Kd,O=S(=O)(Nc1cccc(NS(=O)(=O)c2cccc3ccccc23)c1)c1cccc2ccccc12,59172,,,,
melanoma,DAPK3,O43293,Death-associated protein kinase 3 (DAP kinase 3) (EC 2.7.11.1) (DAP-like kinase) (Dlk) (MYPT1 kinase) (Zipper-interacting protein kinase) (ZIP-kinase),4.41,1.0,Kd,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579,1.0,Kd,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579,1.0,Kd,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579
melanoma,CDC2,P06493,Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase),4.37,0.1,IC50,NS(=O)(=O)c1ccc(Nc2ncc(c(Nc3ccc4nc[nH]c4c3)n2)C(F)(F)F)cc1,50164702,0.23,IC50,O=C1Cc2c([nH]c3ccc(cc23)N(=O)=O)-c2cc(CCC#N)ccc2N1,84533,0.49,IC50,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579
melanoma,PDPK1,O15530,3-phosphoinositide-dependent protein kinase 1 (hPDK1) (EC 2.7.11.1),4.34,0.6,Ki,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCC[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc12,50361648,0.6,Ki,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3COC[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc12,50361649,0.630957,IC50,C[C@@H]1C[C@H](CN(C1)c1cc(nc(N)n1)-c1ccc2c(N)n[nH]c2c1)N(C)C(=O)CC(C)(C)C,50341250
melanoma,TRA1,P14625,Endoplasmin (94 kDa glucose-regulated protein) (GRP-94) (Heat shock protein 90 kDa beta member 1) (Tumor rejection antigen 1) (gp96 homolog),4.28,4.0,Ki,CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O,20926,5.0,Ki,CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)C(C)=CC=C[C@@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2N=CCN(C)C,50445479,,,,
melanoma,HPGD,P15428,15-hydroxyprostaglandin dehydrogenase [NAD(+)] (15-PGDH) (EC 1.1.1.141) (Prostaglandin dehydrogenase 1) (Short chain dehydrogenase/reductase family 36C member 1),4.17,4.0,IC50,Brc1cc(\C=C2/SC(=O)NC2=O)ccc1OCCc1ccccc1,50066953,6.6,IC50,OC1=NC(=O)C(S1)=Cc1ccc(OCCC2CCCCC2)c(Br)c1,50347953,7.2,IC50,OC1=NC(=O)C(S1)=Cc1ccc(OCCC2CCCCC2)c(Cl)c1,50347952
melanoma,DCPS,Q96C86,m7GpppX diphosphatase (EC 3.6.1.59) (DCS-1) (Decapping scavenger enzyme) (Hint-related 7meGMP-directed hydrolase) (Histidine triad nucleotide-binding protein 5) (Histidine triad protein member 5) (HINT-5) (Scavenger mRNA-decapping enzyme DcpS),4.16,7.62,IC50,Nc1nc(N)c2c(OCC3CCN(Cc4ccccc4F)CC3)cccc2n1,50232538,9.38,IC50,Cn1ccnc1CN1CCC(COc2cccc3nc(N)nc(N)c23)CC1,36533,,,,
melanoma,CDC42BPA,Q5VT25,Serine/threonine-protein kinase MRCK alpha (EC 2.7.11.1) (CDC42-binding protein kinase alpha) (DMPK-like alpha) (Myotonic dystrophy kinase-related CDC42-binding kinase alpha) (MRCK alpha) (Myotonic dystrophy protein kinase-like alpha),4.12,5.9,Ki,CCCC(=O)O[C@@]12C(C3CC(=O)C[C@@]4(O)C(C=C(C)C4=O)[C@]3(O)[C@@H](C)[C@H]1OC(=O)c1ccccc1NC)C2(C)C,92596,,,,,,,,
melanoma,CTSD,P07339,Cathepsin D (EC 3.4.23.5) [Cleaved into: Cathepsin D light chain; Cathepsin D heavy chain],4.06,0.00143,Ki,CC(C)(C)OC(=O)NN(CC(=O)N(Cc1ccccc1)Cc1ccccc1)C#N,50030745,0.0042,Ki,CN(Cc1ccccc1)C(=O)CN(NC(=O)OC(C)(C)C)C#N,50030746,0.01,Ki,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O,912
melanoma,PKN2,Q16513,Serine/threonine-protein kinase N2 (EC 2.7.11.13) (PKN gamma) (Protein kinase C-like 2) (Protein-kinase C-related kinase 2),4.05,1.8,Kd,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,50308060,1.8,Kd,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,50308060,2.2,IC50,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13,2579
melanoma,SLC29A1,Q99808,"Equilibrative nucleoside transporter 1 (Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter) (Equilibrative NBMPR-sensitive nucleoside transporter) (Nucleoside transporter, es-type) (Solute carrier family 29 member 1)",4.0,0.018000000000000002,Ki,O[C@@H]1[C@@H](CSCCNC(=O)CCCCCNC(=O)c2cccc(I)c2)O[C@H]([C@@H]1O)n1cnc2c(NCc3ccc(cc3)[N+]([O-])=O)ncnc12,50301066,0.064,Ki,O[C@@H]1[C@@H](CSCCNC(=O)CCCCCNC(=O)c2ccc(F)cc2)O[C@H]([C@@H]1O)n1cnc2c(NCc3ccc(cc3)[N+]([O-])=O)ncnc12,50301067,0.26,Kd,O[C@@H]1[C@@H](CSCCNC(=O)CCCCCNC(=O)c2ccc3c(c2)C(=O)OC32C3=C(CC(=O)CC3)Oc3cc(O)ccc23)O[C@H]([C@@H]1O)n1cnc2c(NCc3ccc(cc3)[N+]([O-])=O)ncnc12,50301068
